646 related articles for article (PubMed ID: 15863037)
1. FGF23 and disorders of phosphate homeostasis.
Yu X; White KE
Cytokine Growth Factor Rev; 2005 Apr; 16(2):221-32. PubMed ID: 15863037
[TBL] [Abstract][Full Text] [Related]
2. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.
Quarles LD
Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E1-9. PubMed ID: 12791601
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor 23 and its receptors.
Yu X; White KE
Ther Apher Dial; 2005 Aug; 9(4):308-12. PubMed ID: 16076372
[TBL] [Abstract][Full Text] [Related]
4. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.
ADHR Consortium
Nat Genet; 2000 Nov; 26(3):345-8. PubMed ID: 11062477
[TBL] [Abstract][Full Text] [Related]
5. Emerging role of a phosphatonin in mineral homeostasis and its derangements.
Bielesz B
Eur J Clin Invest; 2006 Aug; 36 Suppl 2():34-42. PubMed ID: 16884396
[TBL] [Abstract][Full Text] [Related]
6. Fibrous dysplasia, phosphate wasting and fibroblast growth factor 23.
Imel EA; Econs MJ
Pediatr Endocrinol Rev; 2007 Aug; 4 Suppl 4():434-9. PubMed ID: 17982392
[TBL] [Abstract][Full Text] [Related]
7. Serum FGF23 levels in normal and disordered phosphorus homeostasis.
Weber TJ; Liu S; Indridason OS; Quarles LD
J Bone Miner Res; 2003 Jul; 18(7):1227-34. PubMed ID: 12854832
[TBL] [Abstract][Full Text] [Related]
8. A familial disorder with low bone density and renal phosphate wasting.
Grondel IM; van der Deure J; Zanen AL; Dogger M; van den Heuvel LP
Eur J Intern Med; 2009 Sep; 20(5):503-8. PubMed ID: 19712854
[TBL] [Abstract][Full Text] [Related]
9. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets.
Imel EA; Hui SL; Econs MJ
J Bone Miner Res; 2007 Apr; 22(4):520-6. PubMed ID: 17227222
[TBL] [Abstract][Full Text] [Related]
10. The wrickkened pathways of FGF23, MEPE and PHEX.
Rowe PS
Crit Rev Oral Biol Med; 2004 Sep; 15(5):264-81. PubMed ID: 15470265
[TBL] [Abstract][Full Text] [Related]
11. Three novel mutations of the PHEX gene in three Chinese families with X-linked dominant hypophosphatemic rickets.
Xia W; Meng X; Jiang Y; Li M; Xing X; Pang L; Wang O; Pei Y; Yu LY; Sun Y; Hu Y; Zhou X
Calcif Tissue Int; 2007 Dec; 81(6):415-20. PubMed ID: 18046499
[TBL] [Abstract][Full Text] [Related]
12. PHEX, FGF23, DMP1 and beyond.
Strom TM; Jüppner H
Curr Opin Nephrol Hypertens; 2008 Jul; 17(4):357-62. PubMed ID: 18660670
[TBL] [Abstract][Full Text] [Related]
13. Regulation of phosphate homeostasis in infants, children, and adolescents, and the role of phosphatonins in this process.
Garabedian M
Curr Opin Pediatr; 2007 Aug; 19(4):488-91. PubMed ID: 17630616
[TBL] [Abstract][Full Text] [Related]
14. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease.
Stubbs J; Liu S; Quarles LD
Semin Dial; 2007; 20(4):302-8. PubMed ID: 17635819
[TBL] [Abstract][Full Text] [Related]
15. Bone as a source of FGF23: regulation by phosphate?
Mirams M; Robinson BG; Mason RS; Nelson AE
Bone; 2004 Nov; 35(5):1192-9. PubMed ID: 15542045
[TBL] [Abstract][Full Text] [Related]
16. Novel regulators of phosphate homeostasis and bone metabolism.
Jüppner H
Ther Apher Dial; 2007 Oct; 11 Suppl 1():S3-22. PubMed ID: 17976082
[TBL] [Abstract][Full Text] [Related]
17. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.
Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T
Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126
[TBL] [Abstract][Full Text] [Related]
18. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.
Shimada T; Mizutani S; Muto T; Yoneya T; Hino R; Takeda S; Takeuchi Y; Fujita T; Fukumoto S; Yamashita T
Proc Natl Acad Sci U S A; 2001 May; 98(11):6500-5. PubMed ID: 11344269
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
Jonsson KB; Zahradnik R; Larsson T; White KE; Sugimoto T; Imanishi Y; Yamamoto T; Hampson G; Koshiyama H; Ljunggren O; Oba K; Yang IM; Miyauchi A; Econs MJ; Lavigne J; Jüppner H
N Engl J Med; 2003 Apr; 348(17):1656-63. PubMed ID: 12711740
[TBL] [Abstract][Full Text] [Related]
20. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.
Sitara D; Razzaque MS; Hesse M; Yoganathan S; Taguchi T; Erben RG; Jüppner H; Lanske B
Matrix Biol; 2004 Nov; 23(7):421-32. PubMed ID: 15579309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]